Overview

Open-Label Safety Study of Solriamfetol in Subjects with Binge Eating Disorder

Status:
ENROLLING_BY_INVITATION
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, multi-center, open-label study to evaluate the long-term safety and efficacy of solriamfetol in the treatment of binge eating disorder (BED) in adults.
Phase:
PHASE3
Details
Lead Sponsor:
Axsome Therapeutics, Inc.
Treatments:
solriamfetol